Board of Directors
Jennifer A. Baird, President and CEO, Accuri Cytometers, Inc. has led teams of technology developers, process improvement and sales/marketing groups generating significant cost savings, new products and sales for her clients and employers. As a Vice President at Keane Consulting Group she helped build the company as it quintupled in size to over 150 staff and managed over $10M in projects. At ISSYS Sensing Systems, Inc (MI), Ms. Baird led fundraising, marketing/sales, business development, grant proposal writing, public relations, regulatory affairs, human resources, and product development.
Ms. Baird holds a BA in Organizational Psychology from the University of Michigan and an MBA from Kellogg Graduate School of Management, where she shared Top-of-Class honors.
Daniel J. Calvo, President and CEO, Assay Designs, Inc. has more than 25 years experience in life and health sciences. Most recently, he was CEO of Cellomics, Inc., the leader in the High Content Screening market, which was acquired by Fisher Scientific International Prior to that, Dan was VP, Worldwide Sales and Service at PerkinElmer Life and Analytical Sciences, a leading global provider of instruments, reagents, software and services for the life sciences, drug discovery and diagnostics markets. In his role at Perkin Elmer, Dan led the integration and expansion of PerkinElmer's life science business, growing from $200 million to $500 million. Dan was Senior VP, Global Sales and Marketing for NEN Life Sciences, where he drove a significant turnaround of the company prior to the acquisition by PerkinElmer. He spent more than 15 years at DuPont in various sales, marketing and operational assignments in their Medical Products business. Dan also serves as Chairman of the board of directors for Optra Systems, an India-based imaging software company, as well as being a member of the board of directors for Decision Biomarkers and MICHBIO.
Dan received an AB degree in biochemistry from Princeton University, an MHS in Environmental Health Engineering from The Johns Hopkins University and an MBA in Business Administration from Bellarmine College.
George W. Dunbar, President and Chief Executive Officer, Aastrom Biosciences, Inc. and a member of Aastrom's Board of Directors, has more than thirty years of experience in the healthcare field, including the biotech, pharmaceutical, diagnostic and device sectors. During this period, he has spent more than fifteen years as a chief executive officer of established and early-stage lifesciences companies. Most recently he was the Chief Executive Officer of Quantum Dot Corporation. Prior to that, he was Chief Executive Officer of Targesome, Inc. George also served as Chief Executive Office of Epic Therapeutics. Prior to that, he served at various times as Chief Executive Officer of Cytotherapeutics, Stem Cells, Inc. and Metra Biosystems, and in management positions with the Ares-Serono Group and Amersham International.
George received a B.S. in Electrical Engineering and an MBA from Auburn University. He currently serves on the board of directors of Sonus Pharmaceuticals as well as on the MBA Advisory Board of the Auburn University College of Business.
Bahaa Fam, Venture Partner, Fidelity Biosciences, was a portfolio manager at Fidelity Investment prior to joining Fidelity Biosciences. In that capacity he managed Large and Mid Cap growth equity portfolios for retail and institutional clients. From 1998 through 2004, Bahaa was Fidelity's director of quantitative research where he led a team involved in the design of valuation, equity selection and asset allocation models and strategies. Prior to joining Fidelity, Bahaa was managing director and consulting scientist at the MITRE Corporation, a research & development company of more than 5000 scientists and engineers. While at MITRE, Bahaa directed efforts in the areas of image and signal processing, novel algorithms/computational methods, medical imaging, and mathematical economics as well as activities involving the design of technology and research portfolios. Bahaa currently serves on the board (National Advisory Council) of The Whiting School of Engineering at The Johns Hopkins University and is a member of the board of directors of US Genomics.
Bahaa earned a Bachelor of Science degree in electrical engineering and computer science and a Master of Science degree with a concentration in optimization theory and economic systems from The John Hopkins University.
Thomas C. Kinnear, PhD., Professor of Entrepreneurial Studies at the University of Michigan and Executive Director, Samuel Zell and Robert H. Lurie Institute for Entrepreneurial Studies, Professor Kinnear is a recognized expert in marketing management and research, and is a Director and Vice Chair of the American Marketing Association Foundation. He is active in the entrepreneurial community as a co-founder, advisor, equity investor and a limited partner in four Michigan-based venture funds.He distinguished himself as the University of Michigan's former Vice President of Development and the Business School's D. Maynard Phelps Professor of Marketing. In 1997, he was awarded the Eugene Applebaum Professorship of Entrepreneurial Studies.
Professor Kinnear holds a Ph.D. from the University of Michigan, an MBA from Harvard Business School, and a bachelor's degree from Queens College.
Tim Petersen, Managing Director, Arboretum Ventures, in 2002, joined partner Jan Garfinkle in launching Arboretum Ventures. Tim serves on the Board of Directors of Advanced ICU Care, HealthMedia, and KFx Medical, four of Arboretum's portfolio investments, and previously sat on the Board of Asterand (LSE: ATD). Immediately prior to Arboretum, Tim was the Managing Director of the Zell Lurie Institute for Entrepreneurial Studies at the University of Michigan. He also directed the activities of the Wolverine Venture Fund, an evergreen fund that includes the active participation of Michigan's MBA students. Previously, Tim spent nine years at Industrial Economics, Inc., becoming a member of the firm's senior management team in 1991. Industrial Economics, founded in the early 1980's in Cambridge, MA, is a leader in the fields of natural resource economics and environmental science.
Tim holds a BA in Economics from Williams College, an MS in Economics from the University of Wisconsin, and an MBA from the University of Michigan. Tim serves on a number of advisory boards, including the Michigan Universities Commercialization Initiative and the Biogenerator (St. Louis).
Peter K. Shagory, Partner, Baird Venture Partners. Pete joined BVP in early 2004 and oversees the healthcare and life sciences investment effort. Prior to BVP Pete spent five years at Vector Fund Management, L.P., a life sciences venture capital firm, investing broadly across the medical device and biotechnology fields. Prior to VFM, he spent over six years in corporate finance, mergers & acquisitions and merchant banking at J.P. Morgan & Co. and Banc One Capital Corporation. Pete is currently Board Chairman of Accuri Cytometers and Caden Biosciences, a member of the board of directors of Arbor Surgical Technologies, NimbleGen Systems, and PharMEDium Healthcare, and is a board observer at Aptus Endosystems and Celleration. Pete also serves on the Board of the Wisconsin Biotechnology and Medical Device Association.
Pete received a BS in Business Administration and Finance from Miami University in Oxford, Ohio and a MBA from the Tuck School of Business at Dartmouth College.
Harry W. Wilcox, Chief Financial Officer and Partner, Flagship Ventures joined in 2006, bringing a rich set of experiences and expertise in financial management, operations, fund management and strategy. His career spans 28 years and has involved many different roles and functions including Controller, CFO, Sr. VP BD and CEO. He has also served on several Boards of Directors. In addition to his corporate experience, Harry was previously CFO of two venture capital firms, Highland Capital Partners where he was the founding CFO and General Partner, and prior to that, Charles River Ventures.
Most recently he has served as CFO and then Sr. VP Corporate Development for EXACT Sciences, a Flagship Ventures portfolio company, and on the Board of another portfolio company, Epitome Biosystems. In addition to EXACT Sciences, during the last three years Harry has led an active consulting practice which included roles as interim CEO of two biotech companies; Thrasos Therapeutics and Biostrum. Prior to this, Harry was Executive Vice President, Chief of Finance and Corporate Development of Pyrosequencing, a publicly-held biotech company. Earlier, he had been the President and Chief Executive Officer of Cambridge NeuroScience, Inc. until its sale to CeNeS Pharmaceuticals, and before that Sr. VP Business Development and CFO of Cellcor.
As CFO and Partner at Flagship Ventures, Harry manages all financial operations and LP relations/fundraising. He also serves as a member of the investment team and plays a role as board member or advisor to select portfolio companies. Currently Harry serves as a Director at Epitome Biosystems, Seahorse Biosystems and Visen Medical, and works closely with EXACT Sciences (Nasdaq: EXAS).